BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series
Sign Up to like & getrecommendations! Published in 2020 at "Skeletal Radiology"
DOI: 10.1007/s00256-020-03665-9
Abstract: BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential… read more here.
Keywords: melanoma; inhibitor; panniculitis; metastatic melanoma ... See more keywords
Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells.
Sign Up to like & getrecommendations! Published in 2022 at "Toxicological research"
DOI: 10.1007/s43188-021-00109-x
Abstract: Long-term treatment with oncogenic BRAF inhibitors confers resistance to BRAF inhibitor monotherapy. In this study, a combination treatment strategy with autophagy inhibitors was proposed to increase the sensitivity of BRAF mutant containing A375P melanoma cells… read more here.
Keywords: braf inhibitor; braf; inhibition; increase ... See more keywords
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.489
Abstract: This corrects the article DOI: 10.1038/bjc.2017.85 read more here.
Keywords: concomitant interrupted; inhibitor therapy; braf inhibitor; interrupted braf ... See more keywords
Abstract 3518: Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3518
Abstract: Tumor cell metabolism is a hallmark of chemoresistance and its role has been well-defined in BRAF inhibitor resistance in melanoma. Melanoma cells are highly proliferative and are shown to develop addiction towards the metabolic pathways… read more here.
Keywords: melanoma; treatment; piperlongumine; braf inhibitor ... See more keywords
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-17-0211
Abstract: Alterations in MEK1/2 occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in BRAF-V600E–mutant melanoma and colorectal cancer. Efforts were undertaken to understand the effects of… read more here.
Keywords: inhibition; braf inhibitor; activity; mek1 alterations ... See more keywords
Combined BRAF and MEK Inhibition in Patients with unresectable or metastatic cutaneous melanoma: A meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e21030
Abstract: e21030 Background: Malignant melanoma is a dangerous disease with increasing incidence. Over the past several years, medical advancements have allowed for markedly improved therapeutic options. In patients with BRAF V600E or V600K mutations, the use… read more here.
Keywords: patients unresectable; braf inhibitor; combination; melanoma ... See more keywords
Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.21059
Abstract: Background BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma (cuSCC) is an adverse event associated with these drugs. The contribution of BRAF inhibitor and… read more here.
Keywords: braf mek; braf; mek inhibitors; braf inhibitor ... See more keywords
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Life Science Alliance"
DOI: 10.26508/lsa.202201445
Abstract: The loss of MST2 pathway protein expression in BRAF inhibitor resistant melanoma cells is due to ubiquitination and subsequent proteasomal degradation and prevents MST2-mediated apoptosis. The RAS-RAF-MEK-ERK pathway is hyperactivated in most malignant melanomas, and… read more here.
Keywords: melanoma; resistance; mst2 pathway; pathway ... See more keywords
Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246077
Abstract: Simple Summary Approximately 60% of all melanoma patients have cancer with an activating BRAF mutation that can be effectively treated with a BRAF inhibitor. Unfortunately, such treatment often leads to rapid development of BRAF inhibitor-resistance.… read more here.
Keywords: melanoma; brafi; melanoma cells; activity ... See more keywords
Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology reports"
DOI: 10.3892/or.2020.7582
Abstract: Metastatic melanoma is the most aggressive skin cancer. Although BRAF inhibitor treatment has achieved great success in melanoma, resistance develops within 12 months. Icariside II (IS), a natural compound extracted from Herba Epimedii, exerts anticancer properties. In the… read more here.
Keywords: melanoma; inhibitor resistance; ros production; braf inhibitor ... See more keywords